Cardiac extracellular matrix undergoes extensive and continuous turnover involved in the lesion reparation process, such as in cardiac remodeling, in hypertensive cardiac hypertrophy, in dilated cardiomyopathy, after ...Cardiac extracellular matrix undergoes extensive and continuous turnover involved in the lesion reparation process, such as in cardiac remodeling, in hypertensive cardiac hypertrophy, in dilated cardiomyopathy, after myocardial infarction in the transition to heart failure, and during the progression of left ventricular dysfunction. This report discusses most recent experimental findings and focuses on the alterations in nonmyocytic elements that are a part of heart involvement. Particular attention was given to factors that are responsible for exaggerated myocardial deposition of collagen that may be responsible for ventricular dysfunction.展开更多
慢性完全闭塞（chronic total occlusion，CTO）病变通常被认为是冠心病经皮冠状动脉介入治疗（PCI）中“最后待以攻克的堡垒”。近年来随着手术器械的不断改进、术者经验和技术的提高，尤其是逆向导引钢丝技术的应用，使CTO-PCI的手术...慢性完全闭塞（chronic total occlusion，CTO）病变通常被认为是冠心病经皮冠状动脉介入治疗（PCI）中“最后待以攻克的堡垒”。近年来随着手术器械的不断改进、术者经验和技术的提高，尤其是逆向导引钢丝技术的应用，使CTO-PCI的手术成功率得以显著提高[1-4]。本文将结合中国国情，从实战角度对逆向导引钢丝技术在CTO-PCI中的应用做一论述。展开更多
生物可吸收支架被誉为冠状动脉介入治疗的第四次革命性进展。新一代薄壁生物可吸收支架克服了前一代支架梁较厚的劣势,同时能保持良好的径向支撑力,具有替代前一代的潜力。由上海脉全医疗器械有限公司研发的BIOMAGIC支架,厚度为130μm,...生物可吸收支架被誉为冠状动脉介入治疗的第四次革命性进展。新一代薄壁生物可吸收支架克服了前一代支架梁较厚的劣势,同时能保持良好的径向支撑力,具有替代前一代的潜力。由上海脉全医疗器械有限公司研发的BIOMAGIC支架,厚度为130μm,置入冠状动脉后预期在3~5年内完全吸收。首例接受BIOMAGIC支架置入的患者为33岁女性,诊断为稳定型心绞痛。冠状动脉造影提示左前降支近段重度狭窄,置入一枚3.0 mm×15 mm BIOMAGIC支架。术后3年随访,患者无缺血相关症状,冠状动脉造影和光学相干断层成像显示左前降支支架置入部位仍保持通畅,支架表面内膜覆盖完整,支架梁已部分吸收。展开更多
文摘Cardiac extracellular matrix undergoes extensive and continuous turnover involved in the lesion reparation process, such as in cardiac remodeling, in hypertensive cardiac hypertrophy, in dilated cardiomyopathy, after myocardial infarction in the transition to heart failure, and during the progression of left ventricular dysfunction. This report discusses most recent experimental findings and focuses on the alterations in nonmyocytic elements that are a part of heart involvement. Particular attention was given to factors that are responsible for exaggerated myocardial deposition of collagen that may be responsible for ventricular dysfunction.
文摘慢性完全闭塞（chronic total occlusion，CTO）病变通常被认为是冠心病经皮冠状动脉介入治疗（PCI）中“最后待以攻克的堡垒”。近年来随着手术器械的不断改进、术者经验和技术的提高，尤其是逆向导引钢丝技术的应用，使CTO-PCI的手术成功率得以显著提高[1-4]。本文将结合中国国情，从实战角度对逆向导引钢丝技术在CTO-PCI中的应用做一论述。
文摘生物可吸收支架被誉为冠状动脉介入治疗的第四次革命性进展。新一代薄壁生物可吸收支架克服了前一代支架梁较厚的劣势,同时能保持良好的径向支撑力,具有替代前一代的潜力。由上海脉全医疗器械有限公司研发的BIOMAGIC支架,厚度为130μm,置入冠状动脉后预期在3~5年内完全吸收。首例接受BIOMAGIC支架置入的患者为33岁女性,诊断为稳定型心绞痛。冠状动脉造影提示左前降支近段重度狭窄,置入一枚3.0 mm×15 mm BIOMAGIC支架。术后3年随访,患者无缺血相关症状,冠状动脉造影和光学相干断层成像显示左前降支支架置入部位仍保持通畅,支架表面内膜覆盖完整,支架梁已部分吸收。
